Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Aura Biosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOSTON, JULY 08, 2026 (GLOBE NEWSWIRE) -- AURA BIOSCIENCES, INC. (NASDAQ: AURA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING PRECISION THERAPIES FOR SOLID TUMORS DESIGNED TO PRESERVE ORGAN FUNCTION, TODAY ANNOUNCED THE APPOINTMENT OF JEREMY BENDER, PH.D., M.B.A., TO ITS BOARD OF DIRECTORS.

AURA BIOSCIENCES ANNOUNCES APPOINTMENT OF JEREMY BENDER, PH.D., M.B.A., TO BOARD OF DIRECTORS

VANCOUVER, BRITISH COLUMBIA--(NEWSFILE CORP. - JUNE 17, 2026) - AURANOVA RESOURCES INC. (TSXV: AURA) ("AURANOVA" OR THE "COMPANY") AND KENORLAND MINERALS LTD. ("KENORLAND") ARE PLEASED TO ANNOUNCE COMPLETE ASSAY RESULTS FROM THE 2026 SPRING (PHASE 3) DIAMOND DRILL PROGRAM AT THE SOUTH UCHI PROJECT (THE "PROJECT"), LOCATED IN THE RED LAKE DISTRICT OF ONTARIO.

AURANOVA AND KENORLAND ANNOUNCE LARGE INTRUSION-RELATED GOLD DISCOVERY AT THE SOUTH UCHI PROJECT, ONTARIO

ENROLLMENT OF 108 PATIENTS COMPLETED IN THE REGISTRATION-ENABLING PHASE 3 COMPASS TRIAL TOPLINE DATA FROM THE 15-MONTH PRIMARY ENDPOINT EXPECTED IN THE SECOND HALF OF 2027 BOSTON, JUNE 01, 2026 (GLOBE NEWSWIRE) -- AURA BIOSCIENCES, INC. (NASDAQ: AURA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING PRECISION THERAPIES FOR SOLID TUMORS DESIGNED TO PRESERVE ORGAN FUNCTION, TODAY ANNOUNCED IT HAS COMPLETED ENROLLMENT OF 108 PATIENTS IN THE PHASE 3 TRIAL EVALUATING BELZUPACAP SAROTALOCAN (BEL-SAR) AS A FRONTLINE TREATMENT FOR PATIENTS WITH EARLY CHOROIDAL MELANOMA. TOPLINE DATA FOR THE 15-MONTH PRIMARY ENDPOINT ARE ANTICIPATED IN THE SECOND HALF OF 2027.

AURA BIOSCIENCES ANNOUNCES ENROLLMENT COMPLETION IN PHASE 3 COMPASS TRIAL OF BEL-SAR IN EARLY CHOROIDAL MELANOMA

BOSTON, MAY 19, 2026 (GLOBE NEWSWIRE) -- AURA BIOSCIENCES, INC. (NASDAQ: AURA) (AURA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING PRECISION THERAPIES FOR SOLID TUMORS DESIGNED TO PRESERVE ORGAN FUNCTION, TODAY ANNOUNCED THAT INDUCEMENT EQUITY AWARDS (COLLECTIVELY, INDUCEMENT AWARDS) WERE GRANTED TO NATALIE HOLLES, AURA'S NEW CHIEF EXECUTIVE OFFICER AND PRESIDENT,ON MAY 19, 2026 (THE GRANT DATE). THE INDUCEMENT AWARDS ARE CONSISTENT WITH THE PREVIOUSLY DISCLOSED TERMS OF MS. HOLLES' OFFER LETTER AND WERE APPROVED BY THE BOARD OF DIRECTORS OF THE COMPANY IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

AURA BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

BOSTON, MAY 12, 2026 (GLOBE NEWSWIRE) -- AURA BIOSCIENCES, INC. (NASDAQ: AURA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING PRECISION THERAPIES FOR SOLID TUMORS DESIGNED TO PRESERVE ORGAN FUNCTION, TODAY ANNOUNCED THATMEMBERS OF ITSSENIOR MANAGEMENT TEAM WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: H.C. WAINWRIGHT 4TH ANNUAL BIOCONNECT INVESTOR CONFERENCE AT NASDAQ ON TUESDAY, MAY 19, 2026.

AURA BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

PHASE 3 COMPASS TRIAL ADVANCING TOWARD ENROLLMENT COMPLETION, SUPPORTING 2H 2027 TOPLINE DATA NATALIE HOLLES APPOINTED CHIEF EXECUTIVE OFFICER AND PRESIDENT AND MEMBER OF THE BOARD OF DIRECTORS STRENGTHENED BALANCE SHEET WITH OVERSUBSCRIBED $299 MILLION EQUITY FINANCING; CASH POSITION EXPECTED TO FUND OPERATIONS INTO 2H 2028 BOSTON, MAY 11, 2026 (GLOBE NEWSWIRE) -- AURA BIOSCIENCES, INC. (NASDAQ: AURA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING PRECISION THERAPIES FOR SOLID TUMORS DESIGNED TO PRESERVE ORGAN FUNCTION, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED RECENT BUSINESS HIGHLIGHTS. WE ARE ENTERING A PIVOTAL PERIOD FOR AURA AS WE ADVANCE OUR PHASE 3 COMPASS TRIAL TOWARD ENROLLMENT COMPLETION AND POTENTIAL REGISTRATION, SAID NATALIE HOLLES, CHIEF EXECUTIVE OFFICER OF AURA BIOSCIENCES.

AURA BIOSCIENCES REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

AMSTERDAM, 6 MAY 2026 (REGULATED INFORMATION) --- AMG CRITICAL MATERIALS N.V. (AMG, EURONEXT AMSTERDAM: AMG) REPORTS FIRST QUARTER 2026 ADJUSTED EBITDA OF $44 MILLION. THIS WAS A 2% IMPROVEMENT COMPARED TO THE $43 MILLION IN THE FOURTH QUARTER OF 2025 AND EXCEEDED OUR GUIDANCE THAT THE FIRST QUARTER 2026 WOULD BE DOWN SEQUENTIALLY. THIS BETTER-THAN-EXPECTED PERFORMANCE IN THE CURRENT QUARTER WAS MAINLY DRIVEN BY AMG VANADIUM WHICH INCLUDED THE CONSOLIDATION OF AURA BEGINNING JANUARY 1, 2026. BEYOND CIRCULAR MOLYBDENUM, AURA BROUGHT RECYCLED TUNGSTEN INTO OUR CRITICAL MATERIALS PORTFOLIO, AND THE TUNGSTEN PRICE PERFORMANCE HELPED THEIR RESULTS. DESPITE ANTICIPATED LOWER CASH GENERATION AT THE BEGINNING OF THE YEAR, AMG ENDED THE QUARTER WITH A STRONG BALANCE SHEET HIGHLIGHTED BY OUR $403 MILLION OF TOTAL LIQUIDITY AS OF MARCH 31, 2026. THIS FIGURE DOES NOT INCLUDE THE $127 MILLION OF PROCEEDS FROM THE CAPITAL INCREASE.

AMG REPORTS BETTER THAN EXPECTED FIRST QUARTER 2026 RESULTS

BOSTON, MAY 05, 2026 (GLOBE NEWSWIRE) -- AURA BIOSCIENCES, INC. (AURA) (NASDAQ: AURA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING PRECISION THERAPIES FOR SOLID TUMORS DESIGNED TO PRESERVE ORGAN FUNCTION, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING. IN THE OFFERING, AURA SOLD (I) 46,099,650 SHARES OF COMMON STOCK, WHICH INCLUDES 6,508,650 SHARES SOLD UPON EXERCISE IN FULL BY THE UNDERWRITERS OF THEIR OPTION TO PURCHASE ADDITIONAL SHARES OF COMMON STOCK IN THE OFFERING, AND (II) IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE AN AGGREGATE OF UP TO 3,800,000 SHARES OF ITS COMMON STOCK AT AN EXERCISE PRICE OF $0.00001 PER PRE-FUNDED WARRANT.

AURA BIOSCIENCES ANNOUNCES CLOSING OF $299 MILLION PUBLIC OFFERING INCLUDING FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

BOSTON, MAY 04, 2026 (GLOBE NEWSWIRE) -- AURA BIOSCIENCES, INC. (AURA) (NASDAQ: AURA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING PRECISION THERAPIES FOR SOLID TUMORS DESIGNED TO PRESERVE ORGAN FUNCTION, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING CONSISTING OF (I) 39,591,000 SHARES OF ITS COMMON STOCK AND (II) IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE AN AGGREGATE OF UP TO 3,800,000 SHARES OF ITS COMMON STOCK AT AN EXERCISE PRICE OF $0.00001 PER PRE-FUNDED WARRANT. IN ADDITION, AURA HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 6,508,650 SHARES OF ITS COMMON STOCK ON THE SAME TERMS AND CONDITIONS. THE OFFERING PRICE OF EACH SHARE OF COMMON STOCK IS $6.00. THE OFFERING PRICE OF EACH PRE-FUNDED WARRANT IS $5.99999.

AURA BIOSCIENCES ANNOUNCES PRICING OF $260 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

BOSTON, MAY 04, 2026 (GLOBE NEWSWIRE) -- AURA BIOSCIENCES, INC. (AURA) (NASDAQ: AURA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING PRECISION THERAPIES FOR SOLID TUMORS DESIGNED TO PRESERVE ORGAN FUNCTION, TODAY ANNOUNCED THE LAUNCH OF AN UNDERWRITTEN PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF COMMON STOCK. IN ADDITION, AURA INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL FIFTEEN PERCENT (15%) OF SHARES OF ITS COMMON STOCK (AND SHARES OF COMMON STOCK UNDERLYING PRE-FUNDED WARRANTS) OFFERED IN THE PUBLIC OFFERING ON THE SAME TERMS AND CONDITIONS. ALL OF THE SHARES OF COMMON STOCK AND PRE-FUNDED WARRANTS TO BE SOLD IN THE OFFERING WILL BE OFFERED BY AURA. THE OFFERING IS SUBJECT TO MARKET CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

Aura Biosciences, Inc.

AURA

Price

Financial Reports

No items found.

Press Releases

Aura Biosciences, Inc.

AURA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

AURA